AgingResearch.NewsJoin free

Phase 1Completed

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Phase I Study of APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Sponsor
Aprea Therapeutics (Industry)
Enrollment
51 enrolled
Conditions
Myeloid Malignancy
Interventions
APR-246; Venetoclax; Azacitidine
Ages
adults, older adults
Registry
NCT04214860

Full record on ClinicalTrials.gov

From the registry

This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.

Primary outcomes

  • To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Registered

  5. Started